FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2741687714> ?p ?o ?g. }

• W2741687714 endingPage "66153" @default.
• W2741687714 startingPage "66137" @default.
• W2741687714 abstract "// Michael Merker 1 , Verena Pfirrmann 1 , Sarah Oelsner 1, 2 , Simone Fulda 3, 4, 5 , Thomas Klingebiel 1 , Winfried S. Wels 2 , Peter Bader 1 and Eva Rettinger 1 1 Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt, Germany 2 Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt, Germany 3 Institute for Experimental Cancer Research in Pediatrics, Goethe University, Frankfurt, Germany 4 German Cancer Consortium (DKTK), Heidelberg, Germany 5 German Cancer Research Center (DKFZ), Heidelberg, Germany Correspondence to: Michael Merker, email: michael.merker@kgu.de Keywords: soft tissue sarcoma, cell therapy, cytokine-induced killer cells, chimeric antigen receptor, pediatric cancer Received: April 04, 2017     Accepted: June 29, 2017     Published: August 02, 2017 ABSTRACT Pediatric patients with recurrent, refractory or advanced soft tissue sarcoma (STS) who are simultaneously showing signs of cumulative treatment toxicity are in need of novel therapies. In this preclinical analysis, we identified ErbB2 as a targetable antigen on STS cells and used cytokine-induced killer (CIK) cells transduced with the lentiviral 2 nd -generation chimeric antigen receptor (CAR) vector pS-5.28.z-IEW to target ErbB2-positive tumors. Solely CIK cell subsets with the CD3 + T cell phenotype showed up to 85% cell surface expression of the respective CAR. A comparison of wildtype (WT), mock-vector and ErbB2-CAR-CIK cells showed, that engineered cells exhibited diminished in vitro expansion, retained WT CIK cell phenotype with higher percentages of differentiated effector memory/effector cells. Activating natural killer (NK) cell receptor NKG2D-restricted target cell recognition and killing of WT and ErbB2-CAR-CIK cells was maintained against ErbB2-negative tumors, while ErbB2-CAR-CIK cells demonstrated significantly increased cytotoxicity against ErbB2-positive targets, including primary tumors. ErbB2-CAR- but not WT CIK cells proliferated, infiltrated and efficiently lysed tumor cell monolayers as well as 3D tumor spheroids. Here, we demonstrate a potential cell therapeutic approach using ErbB2-CAR-CIK cells for the recognition and elimination of tumor cells expressing ErbB2, which we identified as a targetable antigen on high-risk STS cells." @default.
• W2741687714 created "2017-08-08" @default.
• W2741687714 creator A5002564888 @default.
• W2741687714 creator A5009811688 @default.
• W2741687714 creator A5031190509 @default.
• W2741687714 creator A5056700746 @default.
• W2741687714 creator A5059562009 @default.
• W2741687714 creator A5060684796 @default.
• W2741687714 creator A5063179666 @default.
• W2741687714 creator A5080913590 @default.
• W2741687714 date "2017-08-02" @default.
• W2741687714 modified "2023-10-05" @default.
• W2741687714 title "Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children" @default.
• W2741687714 cites W1532326900 @default.
• W2741687714 cites W1647507681 @default.
• W2741687714 cites W1697896484 @default.
• W2741687714 cites W1856961639 @default.
• W2741687714 cites W1948158464 @default.
• W2741687714 cites W1967517831 @default.
• W2741687714 cites W1967995010 @default.
• W2741687714 cites W1979818745 @default.
• W2741687714 cites W1992752045 @default.
• W2741687714 cites W1994284636 @default.
• W2741687714 cites W1998419417 @default.
• W2741687714 cites W2016523043 @default.
• W2741687714 cites W2022881751 @default.
• W2741687714 cites W2023068069 @default.
• W2741687714 cites W2024651005 @default.
• W2741687714 cites W2027863358 @default.
• W2741687714 cites W2031659182 @default.
• W2741687714 cites W2032336088 @default.
• W2741687714 cites W2043904711 @default.
• W2741687714 cites W2048752843 @default.
• W2741687714 cites W2051549641 @default.
• W2741687714 cites W2054491342 @default.
• W2741687714 cites W2061319708 @default.
• W2741687714 cites W2066930712 @default.
• W2741687714 cites W2068890283 @default.
• W2741687714 cites W2069996052 @default.
• W2741687714 cites W2078992149 @default.
• W2741687714 cites W2084832164 @default.
• W2741687714 cites W2087055812 @default.
• W2741687714 cites W2087654677 @default.
• W2741687714 cites W2094945699 @default.
• W2741687714 cites W2096325838 @default.
• W2741687714 cites W2103937028 @default.
• W2741687714 cites W2105400883 @default.
• W2741687714 cites W2110099898 @default.
• W2741687714 cites W2114229735 @default.
• W2741687714 cites W2118796952 @default.
• W2741687714 cites W2120142068 @default.
• W2741687714 cites W2123276057 @default.
• W2741687714 cites W2124637769 @default.
• W2741687714 cites W2124937026 @default.
• W2741687714 cites W2125028197 @default.
• W2741687714 cites W2126189632 @default.
• W2741687714 cites W2129702476 @default.
• W2741687714 cites W2130338247 @default.
• W2741687714 cites W2143709274 @default.
• W2741687714 cites W2145938519 @default.
• W2741687714 cites W2148640099 @default.
• W2741687714 cites W2149516210 @default.
• W2741687714 cites W2150034934 @default.
• W2741687714 cites W2161516155 @default.
• W2741687714 cites W2164524832 @default.
• W2741687714 cites W2288662037 @default.
• W2741687714 cites W2409807463 @default.
• W2741687714 cites W2436952019 @default.
• W2741687714 cites W2472794159 @default.
• W2741687714 doi "https://doi.org/10.18632/oncotarget.19821" @default.
• W2741687714 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5630399" @default.
• W2741687714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29029499" @default.
• W2741687714 hasPublicationYear "2017" @default.
• W2741687714 type Work @default.
• W2741687714 sameAs 2741687714 @default.
• W2741687714 citedByCount "30" @default.
• W2741687714 countsByYear W27416877142018 @default.
• W2741687714 countsByYear W27416877142019 @default.
• W2741687714 countsByYear W27416877142020 @default.
• W2741687714 countsByYear W27416877142021 @default.
• W2741687714 countsByYear W27416877142022 @default.
• W2741687714 countsByYear W27416877142023 @default.
• W2741687714 crossrefType "journal-article" @default.
• W2741687714 hasAuthorship W2741687714A5002564888 @default.
• W2741687714 hasAuthorship W2741687714A5009811688 @default.
• W2741687714 hasAuthorship W2741687714A5031190509 @default.
• W2741687714 hasAuthorship W2741687714A5056700746 @default.
• W2741687714 hasAuthorship W2741687714A5059562009 @default.
• W2741687714 hasAuthorship W2741687714A5060684796 @default.
• W2741687714 hasAuthorship W2741687714A5063179666 @default.
• W2741687714 hasAuthorship W2741687714A5080913590 @default.
• W2741687714 hasBestOaLocation W27416877141 @default.
• W2741687714 hasConcept C10882517 @default.
• W2741687714 hasConcept C114684123 @default.
• W2741687714 hasConcept C121608353 @default.
• W2741687714 hasConcept C126322002 @default.
• W2741687714 hasConcept C142724271 @default.
• W2741687714 hasConcept C143998085 @default.

• next